ArticleCureus2024
Immunohistochemistry Study of Antimicrobial Peptides as a Future Diagnostic and Prognostic Tool for Periprosthetic Joint Infections.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periprosthetic joint infection (PJI) is a reputable complication of arthroplasty surgery. Septic loosening is an implant biofilm-related infection with different characteristics and treatment than aseptic loosening. Misdiagnosing PJI results in choosing an inappropriate treatment and, in most cases, failure to achieve asepsis. The worldwide increase of arthroplasty surgeries forces us to research more accurate ways to detect PJIs earlier, cheaper, and faster. In the current study, we investigated 52 arthroplasty revision surgeries (septic and aseptic) and, using immunohistochemistry staining of periprosthetic tissue, successfully demonstrated an important increase in antimicrobial peptides human β defensin-3 (HBD-3) and cathelicidin (LL-37) in the PJI group. Furthermore, we observed that patients with a positive LL-37 stain were associated with a more reserved prognosis at one-year follow-up. These promising results suggest that antimicrobial peptides HBD-3 and LL-37 could be used as future biomarkers for PJI detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.